Biohaven Surges After Delaying Progression By Up To 70% In A Rare Disease
Investor's Business DailyBiohaven stock jumped Monday after the company’s experimental drug slowed progression in a rare disease with no approved treatments.
The post Biohaven Surges After Delaying Progression By Up To 70% In A Rare Disease appeared first on Investor's Bu…